Pelagos Insurance’s (NYSE:PLGO) Q2 CY2026 EPS Miss Estimates, Stock Drops 12%

Pelagos Insurance (NYSE:PLGO) reported Q2 CY2026 results. Revenue rose 10.3% year on year to $650 million, exceeding Wall Street estimates by 1.6%, according to the company. GAAP EPS was $0.52, 43% below analysts’ consensus. The stock fell 12% to $21.41 after the report.

Original reporting
Published Aug 12, 2026, 10:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 12, 2026, 10:14 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Pelagos Insurance’s (NYSE:PLGO) Q2 CY2026 EPS Miss Estimates, Stock Drops 12% — source image
Decision brief

The 30-second read

$PLGOBearishMed
01

Why it matters

Despite topping revenue expectations, Pelagos missed on GAAP EPS and fell short on BVPS, leading to a 12% immediate stock drop, signaling investors are discounting earnings quality and capital growth.

02

Market read

Traders can use the reported EPS and BVPS misses, plus the same-day 12% decline, to reassess near-term valuation and expectations for underwriting profitability.

03

What to watch

The article notes outlier quarters tied to outsized investment gains/losses; if this quarter’s EPS weakness similarly reflects investment volatility, the market reaction may overstate underlying underwriting trends.

Relevance 8/10Novelty 6/10Timing: after-hours/next-session repricing following Q2 CY2026 results

Background

Pelagos is a specialty insurance and reinsurance provider; the article frames results around revenue growth, net premiums earned, and per-share capital metrics (BVPS).

Company-level read

Ticker impact

$PLGOBearishMedium confidence
Context

Pelagos Insurance reported Q2 CY2026 GAAP EPS of $0.52, 43% below consensus, and the stock dropped 12% to $21.41.

Expected impact

Bearish bias for the next few sessions as traders reprice underwriting profitability and per-share capital metrics.

Evidence & confidence

The article provides concrete per-share misses (EPS and BVPS) alongside a same-day 12% decline, which typically sustains volatility until management clarifies drivers.

Market effects

Highlights that for insurers, revenue beats may not offset EPS and book-value weakness, reinforcing focus on underwriting profitability and capital efficiency.

Primarily US-listed specialty insurance sentiment; limited direct spillover beyond the group.

Low, as the disclosure is company-specific and does not indicate a broader reinsurance or capital-market shock.

Counterpoint

Revenue growth beat (+10.3% YoY) and net premiums earned remain the dominant revenue driver, so the EPS miss could be timing or non-recurring items rather than a structural deterioration.

Key entities

  • Pelagos Insurance

    NYSE-listed specialty insurer reporting Q2 CY2026 results with revenue beat but GAAP EPS miss and BVPS weakness.

  • Wall Street consensus

    Analysts’ EPS and BVPS expectations cited as benchmarks that Pelagos missed.

Related articles

$BWENMed

Broadwind stock falls 6% as Q2 revenue misses estimates despite strong growth

Broadwind Energy Inc. (NASDAQ:BWEN) shares fell about 6% pre-market after Q2 results missed estimates. The company reported a loss from continuing operations of $0.03 per share versus a $0.01 loss consensus, and revenue of $24.3M versus a $36.29M forecast. Revenue rose 67% year over year to $24.3M, with $35.2M new orders and adjusted EBITDA of $1.6M.

$VITLMed

Vital Infrastructure Property Trust: Vital Infrastructure Reports Second Quarter 2026 Results; Advances Over $150 Million of North American Acquisitions

Vital Infrastructure Property Trust (TSX: VITL.UN) reported Q2 2026 results for the three and six months ended June 30, 2026. Net income fell to $0.3 million from $32.6 million a year earlier, while AFFO rose to $0.11 per unit. The REIT generated about $145 million net cash from selling its European portfolio and, after quarter end, bought a Brooklyn health hub for US$89.9 million and agreed to buy a Canadian outpatient facility for about $26.2 million.

$PAASMed

Pan American Silver Q2 Profit Surges

Pan American Silver Corp. (PAAS) reported a sharp rise in second-quarter net earnings, citing higher metal prices and stronger silver production. The update is expected to affect investor views on profitability and cash generation, with related coverage noting realized silver price and free cash flow figures.

$MDCXMed

Medicus Pharma Ltd: Medicus Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Medicus Pharma Ltd. (NASDAQ:MDCX) reported Q2 2026 results for the three and six months ended June 30, 2026, and provided a corporate update. The company said it received FDA “Study May Proceed” authorization for its SkinJect registrational program in Gorlin Syndrome and IRB and FDA feedback for an optimized Teverelix Phase 2 study. Cash was $25.2M at June 30, 2026, with Q2 net loss of $11.7M.